MedTrace Logo

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

NCT06215976 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-08-20

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are:

* To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer.
* To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer

Conditions

  • Muscle-Invasive Bladder Carcinoma

Interventions

DRUG

Metformin Hydrochloride 500 MG

Metformin 500mg tablets twice daily

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Samar Farid · faculty of pharmacy Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-06-01
Completion
2024-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215976 on ClinicalTrials.gov